Stockreport

Dyadic Announces Strategic Partnership Agreement to Develop Affordable Rabies Prophylactics and Vaccines Using its Proprietary C1 Cell Microbial Protein Production Platform

Dyadic International, Inc.  (DYAI) 
NASDAQ:AMEX Investor Relations: dyadic.com
PDF JUPITER, Fla. and BUNNIK, the Netherlands, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), [Read more]